Stifel Downgrades Neumora Therapeutics (NMRA) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Guggenheim Downgrades Neumora Therapeutics (NMRA) to Neutral
March 7, 2025 7:52 AM ESTGuggenheim analyst Yatin Suneja downgraded Neumora Therapeutics (NASDAQ: NMRA) from Buy to Neutral.
The analyst comments "Key Message: Following yesterday's announcement by JNJ that the company is discontinuing its Phase 3 VENTURA program testing aticaprant (KORA) as an adjunctive treatment for major depressive... More
